Immunogenicity and efficacy analyses of EPC002, ECA006, and EPCP009 protein subunit combinations as tuberculosis vaccine candidates-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immunogenicity and efficacy analyses of EPC002, ECA006, and EPCP009 protein subunit combinations as tuberculosis vaccine candidates

Published:2023-06 Issue:26 Volume:41 Page:3836-3846
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Wang Ruihuan,Fan Xueting,Jiang Yi,Li Guilian,Li Machao,Zhao Xiuqin,Luan Xiuli,Deng Yunli,Chen Zixin,Liu Haican,Wan Kanglin

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference54 articles.

1. Global tuberculosis report 2022， Geneva: World Health Organization; 2022. .

2. The fight to end tuberculosis must not be forgotten in the COVID-19 outbreak;Manyazewal;Nat Med,2020

3. Modern subunit vaccines: development, components, and research opportunities;Moyle;ChemMedChem,2013

4. Recent advances in the development of protein- and peptide-based subunit vaccines against tuberculosis;Bellini;Cells,2020

5. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection;Lin;J Clin Invest,2012

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Th1/Th2 cytokines in early peripheral blood of patients with multiple injuries and its predictive value for SIRS: A bioinformatic analysis;SLAS Technology;2024-08

2. Optimizing antigen selection for the development of tuberculosis vaccines;Cell Insight;2024-06

3. Recombinant BCG vaccine expressing multistage antigens of Mycobacterium tuberculosis provides long-term immunity against tuberculosis in BALB/c mice;Human Vaccines & Immunotherapeutics;2024-01-23

4. Comparison of the Immunogenicity and Efficacy of rBCG-EPCP009, BCG Prime-EPCP009 Booster, and EPCP009 Protein Regimens as Tuberculosis Vaccine Candidates;Vaccines;2023-11-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3